Mobile site search icon.
Mobile navigation icon.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

TAKHZYRO (lanadelumab-flyo) is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in patients ≥2 years of age.

Establish Treatment expectations and goals

Setting HAE treatment
expectations 1

HAE is a genetic, unpredictable, and lifelong condition, and it's important to set specific goals for therapy.

Choosing effective prevention with TAKHZYRO means working together with your patients to help prevent and reduce the severity of their HAE attacks—which may align with their treatment goals.

Create a regular check-in schedule to review progress and treatment goals—as routine monitoring is recommended by the 2020 HAEA guidelines.

A real TAKHZYRO® patient, Soraya, sitting on a bench outside.

Give TAKHZYRO 2.5 months to reach steady state (for patients age 12 and older)1

Graph indicating the steady state with TAKHZYRO® that occurs after about 70 days.

Encourage your patients to keep taking TAKHZYRO exactly as you prescribed. TAKHZYRO has a half-life of ~14 days, allowing it to be taken every 2 weeks. Because of this, it can take up to 6 doses (10 weeks) to reach steady state.1

Challenge your patient to make a commitment to themselves and TAKHZYRO
Take each dose as prescribed

TAKHZYRO continues to work as it is taken, so it is important to tell your patients to take each dose as prescribed. Remember to impress upon them to avoid skipping or missing doses.

Breakthrough attacks

It is normal for patients to experience breakthrough attacks.1,3

It is recommended that patients keep their on-demand medication on hand in case of a breakthrough attack.

Let your patient know that if a breakthrough attack happens, they should not be discouraged. They should keep taking TAKHZYRO as prescribed and discuss their experience with you.1,3

Stay the course

Over time, your patient may begin to notice that their attacks are less severe or that they are using their on-demand treatment less. These are signs that TAKHZYRO is working.

Long-term prevention.
Long-term support.

Find suggestions for helping your patients stay on top of preventing HAE attacks with TAKHZYRO.

Keep patients on track

HCP and patient resources

Find materials and forms to help get patients started on TAKHZYRO.

See resources

1. Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema. J Allergy Clin Immunol Pract. 2021;9(1):132-150.e3. doi:10.1016/j.jaip.2020.08.046